Literature DB >> 1961647

Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation.

J F Vander1, J S Duker, W E Benson, G C Brown, J A McNamara, R B Rosenstein.   

Abstract

The authors assessed the relationship between early objective response to panretinal photocoagulation (PRP) and the subsequent long-term visual outcome in 59 eyes of 59 consecutive patients who developed proliferative diabetic retinopathy while under the care of a retinal specialist. Thirty five eyes (59%) had regression of high-risk retinopathy characteristics within 3 months of treatment. Eighteen of these eyes (52%) had a final visual acuity of 20/20 or better with a mean follow-up of more than 4 years. Only 2 of the 24 nonresponder eyes (8%) had visual acuity of 20/20 or better. Thirteen of the responder eyes (37%) sustained a delayed vitreous hemorrhage, which was usually self-limited. Three responders underwent vitrectomy with excellent visual results. The authors conclude that the beneficial effect of PRP on visual outcome is directly related to the regression of retinopathy risk factors and that the long-term visual prognosis in high-risk eyes manifesting a favorable initial response to PRP is excellent.

Entities:  

Mesh:

Year:  1991        PMID: 1961647     DOI: 10.1016/s0161-6420(91)32085-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  28 in total

1.  Laser treatment of diabetic retinopathy.

Authors:  P E Tornambe
Journal:  West J Med       Date:  1992-10

2.  Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.

Authors:  André Messias; José Afonso Ramos Filho; Katharina Messias; Felipe P P Almeida; Rogério A Costa; Ingrid U Scott; Florian Gekeler; Rodrigo Jorge
Journal:  Doc Ophthalmol       Date:  2012-03-29       Impact factor: 2.379

3.  Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy.

Authors:  Ai-Yi Zhou; Chen-Jing Zhou; Jing Yao; Yan-Long Quan; Bai-Chao Ren; Jian-Ming Wang
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

4.  Cost savings associated with detection and treatment of diabetic eye disease.

Authors:  J C Javitt
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

Review 5.  A review of anti-VEGF agents for proliferative diabetic retinopathy.

Authors:  P Osaadon; X J Fagan; T Lifshitz; J Levy
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

Review 6.  [VEGF inhibitors in vitreoretinal interventions].

Authors:  N Feltgen; A Stahl
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

7.  Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.

Authors:  Chang-Sue Yang; Kuo-Che Hung; Yi-Ming Huang; Wen-Ming Hsu
Journal:  J Ocul Pharmacol Ther       Date:  2013-03-15       Impact factor: 2.671

Review 8.  Current therapy of diabetic retinopathy: laser and vitreoretinal surgery.

Authors:  S R Wilkes
Journal:  J Natl Med Assoc       Date:  1993-11       Impact factor: 1.798

9.  Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

Authors:  Stanislao Rizzo; Federica Genovesi-Ebert; Emanuele Di Bartolo; Andrea Vento; Sofia Miniaci; George Williams
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-02-20       Impact factor: 3.117

10.  Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy.

Authors:  Siamak Moradian; Hamid Ahmadieh; Mohsen Malihi; Masoud Soheilian; Mohammad Hossein Dehghan; Mohsen Azarmina
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-12       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.